---
title: Nicotinic Receptors and Schizophrenia
nct_id: NCT00952393
overall_status: COMPLETED
phase: PHASE1
sponsor: VA Office of Research and Development
study_type: INTERVENTIONAL
primary_condition: Schizophrenia
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00952393.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00952393"
ct_last_update_post_date: 2016-02-05
last_seen_at: "2026-05-12T06:38:50.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Nicotinic Receptors and Schizophrenia

**NCT ID:** [NCT00952393](https://clinicaltrials.gov/study/NCT00952393)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** VA Office of Research and Development
- **Conditions:** Schizophrenia
- **Start Date:** 2010-01
- **Completion Date:** 2014-10
- **CT.gov Last Update:** 2016-02-05

## Brief Summary

The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.

## Detailed Description

3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. The capsules will be administered singly and eventually bid to determine if sustained blood levels comparable to steady state blood levels seen in previous studies can be determined. Safety and EEG effects will be measured.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy volunteers: males and females who are incapable of pregnancy

Exclusion Criteria:

* Medical illnesses requiring acute treatment
* History of seizures
* Substance abuse including nicotine
```

## Arms

- **Pharmacokinetic** (OTHER) — This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.

## Interventions

- **Pharmacokinetic** (DRUG) — Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined

## Primary Outcomes

- **Blood Levels of Drug** _(time frame: 12 hours)_ — This is the plasma level of the drug as determined by high performance liquid chromatography.

## Locations (1)

- VA Eastern Colorado Health Care System, Denver, Denver, Colorado, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.va eastern colorado health care system, denver|denver|colorado|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00952393.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00952393*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*